Category Archives: Biotech

BIO 2014 Takeaway: The Peace Dividend

A surprising take away from the BIO International Convention in San Diego last month is the stark contrast between cooperative industry engagement and an unstable geopolitical order marked by xenophobia, drift and active, often violent government disengagement from the hard work of building common ground. While BIO held 29,000 partnering meetings over four days, convened […]
Also posted in Emerging Markets, Europe, Events, Global | Tagged , , | Leave a comment

Big Biotech Gains Offset Big Pharma Losses

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
Also posted in Deals, Global, Strategy | Tagged , , , , , | Leave a comment

Bureaucratic Roadblocks Threaten Biopharma Growth

Ahead of the BIO International Convention next week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization, writes that protecting intellectual property rights is vital to biopharma innovation. There is a clear link between a country’s rate of economic development and the strength of its intellectual property laws. This is particularly true in knowledge-intensive […]
Also posted in FDA, Guest Blog, IP, Regulatory | Tagged , , , , | Leave a comment

Challenges to the Specialty Business Model

By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
Also posted in Market Access, Strategy | Tagged , , , | Leave a comment

Increase of Biosimilars Will Have “Negative Impact”

A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019. The report cites patent expirations of branded biologics and regulatory clarification as reasons for the prediction that biosimilars will capture the market share after 2019.
Also posted in Events, Gene therapy, Global | Tagged , , | Leave a comment
  • Categories

  • Meta